Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab and Lutikizumab in active psoriatic arthritis
NCT06865105Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised trial of lutikizumab and risankizumab in psoriatic arthritis (PsA) (3 arms), sponsored by AbbVie Inc. Primary endpoints: American College of Rheumatology 50% Response at 16 weeks and Adverse Events at 52 weeks. Started Apr 2025; status: recruiting.
02
Drugs
lutikizumabrisankizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06865105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06865105.